Apple is in a legal battle with Masimo over blood oxygen monitoring technology. Masimo alleges that Apple’s blood oxygen monitoring feature infringes on its patented technology and accuses Apple of misappropriating trade secrets. Apple denies any wrongdoing. The dispute is being played out in courts and the US International Trade Commission (USITC), with a final verdict expected before Christmas. Apple has halted the sale of Apple Watch Series 9 and Apple Watch Ultra 2 in the US. The outcome could have implications for patent enforcement in the wearable health technology space.
Share via:
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Explained: Apple vs Masimo, what is the blood (oxygen) feud that led to temporary halt of Apple Watch models
Apple is in a legal battle with Masimo over blood oxygen monitoring technology. Masimo alleges that Apple’s blood oxygen monitoring feature infringes on its patented technology and accuses Apple of misappropriating trade secrets. Apple denies any wrongdoing. The dispute is being played out in courts and the US International Trade Commission (USITC), with a final verdict expected before Christmas. Apple has halted the sale of Apple Watch Series 9 and Apple Watch Ultra 2 in the US. The outcome could have implications for patent enforcement in the wearable health technology space.
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi
